Evaluation of the effects and adverse drug reactions of low-dose dexamethasone premedication with weekly docetaxel.
A weekly docetaxel regimen had comparable efficacy with a tri-weekly schedule and caused significantly less severe neutropenia and febrile neutropenia. Therefore, a weekly docetaxel regimen has become increasingly common in cancer treatment. Premedication with corticosteroids can effectively prevent or reduce the severity of hypersensitivity and fluid retention. However, no recommended steroid dosage for a weekly docetaxel regimen has been established to date. The aim of this study is to compare the efficacy and complications of two different weekly docetaxel premedication protocols.



We retrospectively compared the hypersensitivity, hyperglycemia, and infection incidence associated with two weekly docetaxel premedication protocols. The control group (dexamethasone 10 mg intravenously and 4 mg orally every 12 h for four doses, starting 1 h before docetaxel administration) patients started weekly docetaxel chemotherapy between May 2012 and April 2013 at Seoul National University Hospital, and the experimental group (dexamethasone 10 mg intravenously 1 h prior to each docetaxel administration) patients started weekly docetaxel chemotherapy between May 2013 and April 2014.



In total, 109 patients in the control group and 97 patients in the experimental group were included in this study, and there were no statistically significant differences in baseline characteristics between the two groups. The incidence of hypersensitivity and hyperglycemia were similar, but infections were observed significantly less in the experimental group (p = 0.020, OR = 0.408, 0.0190-0.0879).



A low-dose dexamethasone premedication protocol has comparable efficacy in the prevention of docetaxel hypersensitivity with fewer infection complications. Therefore, we recommend a low-dose dexamethasone premedication protocol for weekly docetaxel regimens.
Department of Clinical Pharmacy, College of Pharmacy, Kangwon National University, 1 Kangwondaehak-gil, Chuncheon-si, Gangwon-do, 24341, Republic of Korea.|Department of Pharmacy, Seoul National University Hospital, 101 Daehak-ro, Jongno-gu, Seoul, 03080, Republic of Korea.
Rae Young
RY
Kang
Department of Clinical Pharmacy, College of Pharmacy, Kangwon National University, 1 Kangwondaehak-gil, Chuncheon-si, Gangwon-do, 24341, Republic of Korea.|Korea Pharmaceutical Information Center, 194 Hyoryeong-ro, Seocho-gu, Seoul, 06708, Republic of Korea.
Kyung Sook
KS
Yoo
Department of Pharmacy, Seoul National University Hospital, 101 Daehak-ro, Jongno-gu, Seoul, 03080, Republic of Korea.
Hyeon Ju
HJ
Han
College of Pharmacy, Institute of Pharmaceutical Science and Technology, Hanyang University, 55 Hanyangdaehak-ro, Sangnok-gu, Ansan, Gyeonggi-do, 15588, Republic of Korea.
Ju-Yeun
JY
Lee
Department of Internal Medicine, Seoul National University Hospital, 101 Daehak-ro, Jongno-gu, Seoul, 03080, Republic of Korea.
Se-Hoon
SH
Lee
Department of Internal Medicine, Seoul National University Hospital, 101 Daehak-ro, Jongno-gu, Seoul, 03080, Republic of Korea.
Dong-Wan
DW
Kim
Department of Clinical Pharmacy, College of Pharmacy, Kangwon National University, 1 Kangwondaehak-gil, Chuncheon-si, Gangwon-do, 24341, Republic of Korea. yujeunglee@yahoo.com.
Yu Jeung
YJ
Lee
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects* / Q000494:pharmacology; D003907:Dexamethasone / Q000009:adverse effects* / Q000494:pharmacology; D000077143:Docetaxel; D004334:Drug Administration Schedule; D064420:Drug-Related Side Effects and Adverse Reactions / Q000188:drug therapy*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D011292:Premedication / Q000009:adverse effects*; D012189:Retrospective Studies; D043823:Taxoids / Q000009:adverse effects* / Q000494:pharmacology
D043823:Taxoids; D000077143:Docetaxel; D003907:Dexamethasone
Adverse drug reaction; Dexamethasone; Premedication; Weekly docetaxel
Oncology (Williston Park). 2002 Jun;16(6 Suppl 6):9-15
12108903
Clin Infect Dis. 2011 Feb 15;52(4):e56-93
21258094
Diabet Med. 1998 Jul;15(7):539-53
9686693
Eur J Cancer. 2005 May;41(8):1117-26
15911234
Clin Pharmacol Ther. 1975 Aug;18(2):205-9
1097154
Anticancer Drugs. 2004 Jul;15(6):581-5
15205600
Pharmacotherapy. 2007 Nov;27(11):1512-28
17963461
Oncology. 2005;68(1):71-8
15809523
J Clin Oncol. 2002 Apr 1;20(7):1800-8
11919237
Ann Oncol. 2005 Jan;16(1):90-6
15598944
Nephron Clin Pract. 2007;105(2):c54-7
17135768
Ann Oncol. 2006 Mar;17(3):467-72
16371411
J Clin Oncol. 2001 Aug 1;19(15):3500-5
11481356
N Engl J Med. 2008 Apr 17;358(16):1663-71
18420499
Lancet. 1994 Nov 5;344(8932):1267-72
7967989
Ann Allergy Asthma Immunol. 2009 Mar;102(3):179-87; quiz 187-9, 222
19354063
Support Care Cancer. 2015 Jul;23(7):1969-77
25500718
Ann Oncol. 1993 Aug;4(7):610-1
8103352
Oncologist. 2004;9(5):538-45
15477638
Br J Cancer. 2004 Dec 13;91(12):1996-2004
15558071
Int Arch Allergy Immunol. 2011;156(3):320-4
21720178
J Natl Compr Canc Netw. 2012 Nov 1;10(11):1412-45
23138169
Nature. 1979 Feb 22;277(5698):665-7
423966
Br J Clin Pharmacol. 1997 Jun;43(6):653-8
9205828
Best Pract Res Clin Endocrinol Metab. 2003 Dec;17(4):575-89
14687590
J Oncol Pharm Pract. 2011 Sep;17(3):155-9
20447949
Ann Oncol. 2004 Sep;15(9):1358-65
15319242
Ann N Y Acad Sci. 2004 Jun;1024:124-37
15265777
J Clin Oncol. 2000 Mar;18(6):1212-9
10715290